Background and Aims: Mucosal healing is associated with favourable therapeutic outcomes in patients with ulcerative colitis [UC]. We investigated whether adalimumab concentrations during induction therapy are associated with short-term mucosal healing [STMH] in UC patients. Methods: This was a retrospective, single-centre study including consecutive UC patients treated with adalimumab from June 2005 to May 2014, who underwent an endoscopy both at baseline and after induction therapy [weeks 8-14] and at least one serum sample available at week 2 and/ or week 4. STMH was defined as Mayo endoscopic sub-score of ≤1 with a baseline sub-score of ≥2. Adalimumab concentrations were evaluated using an in-house developed enzyme-linked immunosorbent assay. Results: The study population consisted of 43 patients, the majority of whom [n = 38] 
Introduction
Adalimumab, an anti-tumour necrosis factor [anti-TNF] agent, is an effective treatment for ulcerative colitis [UC] , both in anti-TNF naïve patients and in patients who previously failed infliximab. [1] [2] [3] [4] [5] [6] [7] Objective therapeutic outcomes such as mucosal healing are emerging as primary goals of anti-TNF therapy in inflammatory bowel disease [IBD] . [8] [9] [10] [11] [12] [13] Mucosal healing is associated with favourable long-term therapeutic outcomes including sustained clinical remission and reduced risk of colectomy in patients with UC. [14] [15] [16] [17] [18] The role of proactive therapeutic drug monitoring [TDM] in guiding clinical decisions in IBD patients treated with anti-TNF therapy and a treat-to-target therapeutic approach towards individual, personalized medicine is currently increasing. [19] [20] [21] [22] Exposureresponse studies of anti-TNF agents in UC showed that higher serum drug concentrations are associated with better therapeutic outcomes, including mucosal healing. 4, 14, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Morever a recent meta-analysis showed that higher anti-TNF trough concentrations were associated with higher rates of mucosal healing in IBD. 36 Nevertheless, there are only limited data regarding early TDM of adalimumab in patients with UC. 4 Consequently, a therapeutic range and relevant thresholds for clinical, biomarker and most importantly endoscopic remission are largely unknown.
The main goal of this study was to investigate the association of early adalimumab concentrations with short-term mucosal healing [STMH] in patients with UC.
Methods

Study design, definitions and patient population
This was a retrospective, single-centre study. All patients with moderate to severe UC receiving adalimumab induction therapy [160 and 80 mg at week 0 and 2, respectively] from June 2005 to May 2014 were eligible for the study. Inclusion criteria were endoscopic evaluation of patients both at baseline and after induction therapy, a Mayo endoscopic sub-score ≥2 at baseline, and at least one serum sample available at week 2 and/or week 4. STMH was defined as a Mayo endoscopic sub-score of ≤1, and was assessed at week 8-14. 33 Adalimumab treatment optimization, between week 4 and the time to endoscopy, was defined as a reduction of injection interval from every other week to every week, an increase of the adalimumab dose from 40 to 80 mg, or both. All clinical and endoscopic data were reviewed from the electronic medical records of the patients. Patients gave written informed consent to participate in the Institutional Review Board approved Flemish Study for Research on IBD VLECC registry B322201213950/S53684. Serum samples were prospectively collected and stored at −20 °C.
Serology
Adalimumab concentrations and antibodies to adalimumab [ATAs] were measured at week 2 and/or week 4 in serum samples obtained just before an adalimumab injection, using an in-house developed and clinically validated [drug-sensitive] enzyme-linked immunosorbent assay [ELISA] . 37 The lower limit of detection for adalimumab concentrations was 0.3 µg/ml. The lower detection limit for ATAs was 0.2 µg/ml equivalents. ATAs were not detectable in serum if adalimumab concentration was ≥0.3 µg/ml and such values were regarded as inconclusive for ATAs. Haemoglobin, C-reactive protein [CRP] , white blood cell count, neutrophils, platelets and albumin were measured at baseline by standard procedures. 
Statistical analysis
Results
Study population
The study population consisted of 43 patients [ Figure 1 ]. The majority of patients had a prior failure to infliximab [n = 38, 88.4%]. The reasons for infliximab failure were primary non-response [PNR, n = 5], secondary loss of response [n = 24] and serious adverse event [n = 9; infusion reaction, n = 4]. Disease and patient characteristics are given in Table 1 . Twenty-four and 35 patients had adalimumab serum concentrations available at week 2 and week 4, respectively.
STMH and adalimumab concentration
Twelve patients [27.9%] had STMH. Seven patients had an endoscopic Mayo score of 0, five of whom had a baseline endoscopic Mayo score of 2.
Serum adalimumab concentration at week 4 was statistically significantly higher in patients with STMH compared to those without [ Figure 2 ]. An ROC curve analysis identified a statistically significant adalimumab concentration threshold of 9.4 μg/ ml at week 4 associated with STMH [SN: 67; SP: 77; PPV: 50; NPV: 87] [ Figure 3 ]. However, ROC curve analysis did not identify a statistically significant adalimumab concentration threshold at week 2 associated with STMH [Supplementary Figure 1A] . The relationship between serum adalimumab concentration at week 4 and STMH was further analysed by dividing serum adalimumab concentrations into quartiles. The higher adalimumab serum concentration quartiles at week 4 were associated with higher rates of STMH [ Figure 4 ]. A summary of the factors associated with serum adalimumab concentration quartiles at week 4 is demonstrated in Supplementary As none of the patients had undetectable adalimumab concentrations, all patients were considered inconclusive for ATAs. Consequently, the impact of ATAs on endoscopic outcomes could not be investigated.
Taking into account previous data showing that PNR to infliximab is associated with lack of a short-term clinical response to adalimumab in UC 4 and the fact that in our study none of the five patients with PNR to infliximab achieved STMH, as well as that prior infliximab failure was independently associated with a lack of STMH [ Table 2 ], a sensitivity analysis, by excluding these patients, was also performed. Based on this, serum adalimumab concentration at week 4 was statistically significantly higher in patients with STMH compared to those without [ Supplementary Figure 2 ]. An ROC curve analysis identified a statistically significant adalimumab concentration threshold of 7.5 μg/ml at week 4 associated with STMH [SN: 89; SP: 59; PPV: 47; NPV: 93] [ Supplementary  Figure 3] . However, ROC curve analysis did not identify a statistically significant adalimumab concentration threshold at week 2 associated with STMH [Supplementary Figure 1B] . The higher adalimumab serum concentration quartiles at week 4 were associated with higher rates of STMH [ Supplementary Figure 4] . A summary of the factors associated with serum adalimumab concentration quartiles at week 4 is demonstrated in Supplementary Table 1. 
Factors associated with STMH
Discussion
We demonstrated that early, post-induction higher serum adalimumab concentration is independently associated with STMH. This is in line with previous findings showing an association between mucosal healing and serum adalimumab levels during maintenance therapy in UC. 24, 30 Regarding induction therapy, higher serum infliximab concentrations were previously found to be associated with higher rates of early endoscopic response and mucosal healing in patients with UC. 25, [33] [34] [35] We also identified a serum adalimumab concentration threshold at week 4 of 9.4 µg/ml and 7.5 μg/ml after excluding patients with PNR to infliximab, associated with STMH in UC. These concentration cut-offs are comparable with those reported from previous studies investigating the association of drug levels with mucosal healing during adalimumab maintenance therapy in IBD patients. 24, 30, 31, 38 We also showed that higher baseline mucosal inflammation [endoscopic Mayo score 3] is associated with absence of STMH. Taking this into account along with the fact that in the quartile analysis adalimumab concentration at week 4 associated with STMH did not reach a plateau in our study, it is unknown whether higher serum drug concentrations and higher than 160-80 mg induction doses of adalimumab would lead to higher rates of STMH. A high baseline inflammatory burden with increased drug clearance and faecal loss from an inflammed colon may mandate higher induction dosing of biologicals, and a clinical trial to test higher induction doses of adalimumab is currently ongoing [ClinicalTrials.gov NCT02065622]. 34, [39] [40] [41] Hitherto, there are no clear predicting factors [Supplementary Table 2] for the wide variations in concentrations of anti-TNF monoclonal antibodies. Therefore, it remains to be determined if higher induction dosing can be recommended to increase STMH in all UC patients, especially in those with a baseline endoscopic Mayo score 3 and those with a previous PNR to infliximab, as these factors are independently associated with absence of STMH.
Furthermore, none of the patients with a previous PNR to infliximab achieved STMH on subsequent adalimumab therapy. This is in line with a previous study of our group showing that prior response to infliximab predicts week 12 and year 1 clinical response to adalimumab in UC. 4 The main limitations of this study are its retrospective design related also to some missing values, such as adalimumab concentrations at week 2, the rather small number of patients and the fact that a drug-tolerant assay was not used. In addition, we are unable to establish causation between higher adalimumab serum levels and endoscopic healing. Conversely, healing of the colon may modify adalimumab pharmacokinetics due to a decreased clearance.
In conclusion, this single-centre study, reflecting real-life clinical practice, indicates that adalimumab post-induction concentration is associated with STMH in patients with UC. We hypothesize that pre-emptive early dose optimization may improve therapeutic outcomes. Nevertheless, before a proactive treat-to-trough therapeutic strategy can be applied in clinical practice, large, prospective studies are certainly warranted. 
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